Pay to Marwadi

Company Profile

ALKEM LABORATORIES LTD.

NSE : ALKEMBSE : 539523ISIN CODE : INE540L01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE4899.45112.85 (+2.36 % )
PREV CLOSE (Rs.) 4786.60
OPEN PRICE (Rs.) 4879.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 1450
TODAY'S LOW / HIGH (Rs.)4767.70 4930.00
52 WK LOW / HIGH (Rs.)3211.05 5519.1
NSE4904.00 116.2 (+2.43 % )
PREV CLOSE(Rs.) 4787.80
OPEN PRICE (Rs.) 4793.25
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 4904.00 (196 )
VOLUME 91122
TODAY'S LOW / HIGH(Rs.) 4761.60 4930.00
52 WK LOW / HIGH (Rs.)3186.3 5520

Company Profile

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 1.02
TTM EPS (Rs.) 140.26
P/E Ratio 34.93
Book Value (Rs.) 890.67
Face Value (Rs.) 2
MCap (Rs. in Mn) 585802.74
Price/Earning (TTM) 30.68
Price/Sales (TTM) 6.09
Price/Book (MRQ) 5.50
PAT Margin (%) 11.92
ROCE (%) 13.17
Incorporation Year : 1973

Management Info :

Basudeo N Singh - Chairman Sandeep Singh - Managing Director

Registered Office :

Address : Alkem House,Senapati Bapat Marg,Lower Parel (West),
Mumbai,
Maharashtra-400013

Phone : 022 3982 9999

Website : www.alkemlabs.com

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE
NEWS More
28Mar03-28-2024$Alkem Laboratories incorporates wholly owned subsidiary Alkem Laboratories incorpora

Alkem Laboratories has incorporated Wholly Owned Subsidiary (WOS) of the Company in the name of ‘Alkem Medtech’. The company has incorporated WOS on March 27, 2024 in India. Alkem Medtech has been incorporated for exploring the medical device segment mainly in the cardiovascular and orthopedic fields.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

Alkem Laboratories has incorporated Wholly Owned Subsidiary (WO..
28Mar03-28-2024$USFDA concludes inspection at Alkem Laboratories’ manufacturing facility at Baddi USFDA concludes inspection a

U.S Food and Drug Administration (USFDA) has concluded inspection at Alkem Laboratories’ manufacturing facility located at Baddi, India. The said inspection conducted from March 19, 2024 to March 27, 2024. 

At the end of the inspection, the company has received Form 483 with ten observations. This was a GMP as well as a Pre-Approval Inspection. There is no data integrity observation.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.


U.S Food and Drug Administration (USFDA) has concluded inspecti..
06Mar03-06-2024$Alkem Laboratories informs about notice of postal ballot Alkem Laboratories informs a
Alkem Laboratories has informed that it attached the Postal Ballot Notice dated 09th February, 2024 for the business as specified in the notice. 

The above information is a part of company’s filings submitted to BSE.

Alkem Laboratories has informed that it attached the Postal Bal..
28Feb02-28-2024$USFDA issues EIR for Alkem Laboratories’ API manufacturing facility at Mandva USFDA issues EIR for Alkem L

U.S Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for Alkem Laboratories’ API manufacturing facility located at Mandva, Maharashtra. The inspection has been classified as Voluntary Action Indicated (VAI) and was closed accordingly.

Earlier, USFDA had concluded inspection at the company’s API manufacturing facility located at Mandva, Maharashtra. The said inspection conducted from November 27, 2023 to December 01, 2023. At the end of the inspection, the company has received Form 483 with three observations. 

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.


U.S Food and Drug Administration (USFDA) has issued an Establis..
28Feb02-28-2024$Alkem Laboratories informs about press release Alkem Laboratories informs a
In furtherance to the intimation captioned ‘US FDA Inspection at Company’s API manufacturing facility located at Mandva’ dated 01st December, 2023, Alkem Laboratories has informed that US FDA has issued an Establishment Inspection Report (EIR) for the said manufacturing facility. The Inspection has been classified as Voluntary Action Indicated (VAI) and was closed accordingly.

The above information is a part of company’s filings submitted to BSE.

In furtherance to the intimation captioned ‘US FDA Inspection..
Financials More
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit5042.311344.7
Gross Profit 5343.8 13269.9
Operating Profit 6649.216432.4
Net Sales 24945.990545.5
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Ajanta Pharma (BSE)
 2377.00 (6.44%)
M.Cap ( in Cr)
29930.39
Astrazeneca Pharma I (BSE)
 5424.45 (1.70%)
M.Cap ( in Cr)
13561.13
Dr. Reddy's Lab (BSE)
 6349.95 (0.98%)
M.Cap ( in Cr)
105928.76
Torrent Pharma (BSE)
 2732.60 (2.20%)
M.Cap ( in Cr)
92483.60
Jenburkt Pharma (BSE)
 840.85 (4.94%)
M.Cap ( in Cr)
371.09
Shareholding Pattern More
PROMOTERS 56.74 %
FI/BANKS/INSURANCE 2.75 %
NON-INSTITUTION 18.52 %
MUTUAL FUNDS/UTI 11.92 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS More
F & O Quotes